RS51331B - USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS - Google Patents

USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS

Info

Publication number
RS51331B
RS51331B RSP-2010/0323A RSP20100323A RS51331B RS 51331 B RS51331 B RS 51331B RS P20100323 A RSP20100323 A RS P20100323A RS 51331 B RS51331 B RS 51331B
Authority
RS
Serbia
Prior art keywords
antagonist
pipamperone
receptor antagonist
psychotic disorders
dopamin
Prior art date
Application number
RSP-2010/0323A
Other languages
English (en)
Serbian (sr)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from EP03447279A external-priority patent/EP1547650A1/en
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/en
Priority claimed from EP04025035A external-priority patent/EP1541197B8/en
Priority claimed from US10/984,683 external-priority patent/US20050203130A1/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by Pharmaneuroboost N.V. filed Critical Pharmaneuroboost N.V.
Publication of RS51331B publication Critical patent/RS51331B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RSP-2010/0323A 2003-12-02 2004-12-02 USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS RS51331B (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP03447279A EP1547650A1 (en) 2003-12-02 2003-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (en) 2004-03-18 2004-03-18 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04025035A EP1541197B8 (en) 2003-12-02 2004-10-21 Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
JP2004349085A JP4571485B2 (ja) 2003-12-02 2004-11-04 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US10/984,683 US20050203130A1 (en) 2003-12-02 2004-11-09 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
RS51331B true RS51331B (en) 2011-02-28

Family

ID=42134278

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0323A RS51331B (en) 2003-12-02 2004-12-02 USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS

Country Status (8)

Country Link
AT (1) ATE464901T1 (da)
DE (1) DE602004026781D1 (da)
DK (1) DK1708790T3 (da)
ES (1) ES2343962T3 (da)
HR (1) HRP20100376T1 (da)
PT (1) PT1708790E (da)
RS (1) RS51331B (da)
SI (1) SI1708790T1 (da)

Also Published As

Publication number Publication date
ES2343962T3 (es) 2010-08-13
DK1708790T3 (da) 2010-06-21
SI1708790T1 (sl) 2010-09-30
DE602004026781D1 (de) 2010-06-02
PT1708790E (pt) 2010-07-09
ATE464901T1 (de) 2010-05-15
HRP20100376T1 (hr) 2010-08-31

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
HRP20050077B1 (hr) Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2005515966A5 (da)
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
RS53591B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INTERNAL HEARING DISORDERS
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BR0311701A (pt) Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação
RS52256B (en) THERAPEUTIC USES OF COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITIES
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NO20080244L (no) Doseringsstyring for prasugrel
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
JP2016505050A5 (da)